Relevance of Flavanols for Cardiovascular Function in End-Stage Renal Disease (ESRD)

This study has been withdrawn prior to enrollment.
(no patients recruited, responsible physician left clinic)
Sponsor:
Collaborator:
Heinrich-Heine University, Duesseldorf
Information provided by:
RWTH Aachen University
ClinicalTrials.gov Identifier:
NCT00835887
First received: February 3, 2009
Last updated: September 17, 2009
Last verified: September 2009
  Purpose

In this study, the acute and long-term effects of flavanols on vascular function in patients with ESRD will be investigated.


Condition Intervention Phase
End Stage Renal Disease
Dietary Supplement: low and high dose flavanoids
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Relevance of Flavanols for Cardiovascular Function in End-Stage Renal Disease, a Phase 2 Study

Resource links provided by NLM:


Further study details as provided by RWTH Aachen University:

Primary Outcome Measures:
  • Vascular function [ Time Frame: before treatment, directly after treatment and 3, resp. 4 months afterwards ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Arms Assigned Interventions
Experimental: 1
Treatment with low dose flavanoids
Dietary Supplement: low and high dose flavanoids
treatment with flavanoid-rich or flavanoid-low cacao twice daily
Experimental: 2
Treatment with high dose flavanoids
Dietary Supplement: low and high dose flavanoids
treatment with flavanoid-rich or flavanoid-low cacao twice daily

Detailed Description:

In order to assess potential acute beneficial effects of flavanols in patients with ESRD, 10 patients undergoing dialysis will be recruited. Subjects will receive a cocoa drink with 16 mg, 250 mg, and 500 mg (in 100 mL water each) flavan-3-ols (40% epicatechine/catechine und 60% procyanidine), respectively, on three consecutively days. The functional/hemodynamic parameters (flowmediated dilation (FMD), venous-occlusion-plethysmography (VOP), blood pressure, heart rate), the biochemical marker of the circulating NO pool (nitrite, nitrate, RNOs), and the plasma levels of flavanols (epicatechine and catechine) will be determined before and after ingestion of the respective cocoadrink.

It is expected that flavanols dose-dependently improve vascular function and that this is associated with an increase in the circulating NO pool.

In order to assess long-term effects of flavanols on vascular function in patients with ESRD.

To characterize potential vascular long-term effects of flavanols in patients with ESRD, a placebo-controlled double-blinded randomized control study will be performed in 40 patients randomized in two groups. Patients will daily receive either a flavanol-poor cocoa drink or a flavanol-rich cocoa drink over a period of three months.

The flavanol-dosis that is necessary to affect vascular function will be assessed as described above. At the beginning of the study, after the first intake of the cocoa (in order to identify nonresponders) and monthly for a period of three months the vascular function will be assessed applying innovative imaging techniques to the brachial artery to assess endothelium-dependent regulation of physicomechanical properties and vascular tone and thus blood flow at the level of the macrocirculation. In parallel new techniques will be applied to assess perfusion at the level of the microcirculation. In particular, measurement of flow-mediated dilation, intima-media-thickness,compliance and stiffness indices will be performed in the macrocirculation of the brachial artery.

Considering the microcirculation, new diagnostic approaches such as Laser-Doppler Flow and peripheral arterial tonometry next to diagnostic approaches such as the venous occlusive plethysmography will be performed. Moreover, the circulating NO pool, markers of inflammation and of oxidative stress, the uremic toxin pcresol and the plasma levels of flavanols will be determined. The exams after month 1, 2, and 3 will be performed in the morning before intake of the cocoa drink. In order to examine potential sustained effects, an additional examination day will take place after 4 month (one month after stopping the flavanol-intake). It is expected that the flavanol-rich cocoa will improve vascular function, which is associated with an increase in the circulating NO-pool and a decrease in inflammatory markers and the marker for oxidative stress.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with end stage renal disease

Exclusion Criteria:

  • person under 18 years of age
  • participation in another study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00835887

Locations
Germany
Düsseldorf University Hospital
Düsseldorf, Germany
Sponsors and Collaborators
RWTH Aachen University
Heinrich-Heine University, Duesseldorf
  More Information

No publications provided

Responsible Party: Heinrich-Heine-University Düsseldorf, Department of Medicine, Divison of Cardiology, Pulmonology and Vascular Medicine
ClinicalTrials.gov Identifier: NCT00835887     History of Changes
Other Study ID Numbers: ESRD-Study
Study First Received: February 3, 2009
Last Updated: September 17, 2009
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Kidney Diseases
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency

ClinicalTrials.gov processed this record on April 22, 2014